FLSM
MGX icon

Frazier Life Sciences Management’s Metagenomi Therapeutics MGX Stock Holding History

Frazier Life Sciences Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-245,692
Closed -$1M – 56
2024
Q2 		$1M Sell
245,692
-33,333
-12% -$229K 0.05% 48
2024
Q1 		$2.94M Buy
+279,025
New +$3.21M 0.12% 47

Other funds holding MGX

SVGI
Sozo Ventures GP II Redwood City, California $1.33B AUM 9.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Life Sciences Management's MGX Position: Q3 2024 in Review

Frazier Life Sciences Management sold out of Metagenomi Therapeutics (MGX) in Q3 2024, closing a stake of 245,692 shares — an estimated $1M sold.

Frazier Life Sciences Management first reported a position in MGX in Q1 2024 and held it in 2 quarters. The position peaked at $2.94M in Q1 2024. 67 funds tracked by Wall St. Rank hold MGX as of Q3 2024.

  • Frazier Life Sciences Management reported no remaining Metagenomi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 245,692 Metagenomi Therapeutics shares in Q3 2024, an estimated $1M.
  • Frazier Life Sciences Management first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 2 quarters.
  • Frazier Life Sciences Management's Metagenomi Therapeutics position peaked at $2.94M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2024.

Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.